People and Business News —10/22
People
Alliance Pharma expanded their leadership team by four, bringing on board a new Chief Operating Officer in Jean Pierre Boutrand, Chief Commercial Officer in Vito Saccente, Chief Financial Officer in Glenn Weber, and Susan Woolley as Chief People Officer.
Paradigm Clinical Research announced the appointment of Kurt Mussina as CEO. Additonally, the company announced growth on its executive leadership team, bringing on board Travis Milnes as chief financial officer and Amy Henderson as head of clinical operations.
Sharp, has appointed Robert Feltz as Director, Analytical and Formulation Services and Michael MacNeir as Vice President, Global Business Development.
Trialbee announced the addition of Jo Holton as VP of Global Sales to their company.
TransCelerate announced that, previously COO, Janice Chang, has been appointed Chief Executive Officer.
Business
Recbio Technology Co. contracted OCT Clinical to carry out its phase III clinical study for a SARS-CoV-2 vaccine.
Stayble Therapeutics and OCT Clinical reported that the last patient has been enrolled in the ongoing phase IIb clinical trial of STA363.
dMed |Clinipace announced that it is changing its corporate name to Caidya (pronounced KAY-dee-uh).
Recognition
CluePoints celebrated its tenth anniversary.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
